24/7 Market News Snapshot 08 September, 2025 – Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY)

September 8, 2025

DENVER, Colo., 08 September, 2025 (www.247marketnews.com) – (NASDAQ:ONCY) are discussed in this article.
Oncolytics Biotech, Inc. (NASDAQ:ONCY) has garnered significant investor interest following a notable increase in its share price, which opened today at $1.14 and rose approximately 19.62% to $1.268. The trading volume reached 2.13 million shares, reflecting a surge in activity that may be attributed to positive developments regarding the company’s lead therapeutic candidate, pelareorep.

Recent data unveiled promising results from trials exploring pelareorep’s efficacy in treating KRAS mutant metastatic colorectal cancer (mCRC). Key findings indicate substantial enhancements in patient outcomes, with median progression-free survival (PFS) reported at 16.6 months and median overall survival (OS) at 27.0 months for patients receiving pelareorep alongside standard treatments. In contrast, the current standard of care yields median PFS and OS of only 5.7 and 11.2 months, respectively.

The REO 022 trial and GOBLET study highlight pelareorep’s unique ability to stimulate immune responses within tumors, showcasing its potential to effectively target a patient population traditionally resistant to treatment. The mechanism behind pelareorep’s action includes inducing viral replication in colorectal cancer tumors, further supporting its status as a promising immunotherapy candidate.

In response to these compelling results, Oncolytics is actively seeking to outline a regulatory strategy for future registrational studies. Plans are underway to initiate an investigator-sponsored trial to further validate the drug’s effectiveness in KRAS mutant mCRC patients. Dr. Sanjay Goel from Rutgers University has expressed enthusiasm regarding the potential of pelareorep in addressing urgent needs within this challenging cancer subset.

CEO Jared Kelly emphasized the company’s dedication to propelling pelareorep through strategic collaborations, aiming to enhance treatment outcomes for patients battling aggressive malignancies and reinforce Oncolytics’ position at the forefront of innovative cancer therapies.

Related news for (ONCY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.